Clinical Trials Logo
  1. Home
  2. Migraine
  3. NCT00777218
  4. Details
NCT00777218 Clinical Trial

Cognitive Side Effects of Commonly Prescribed Medications in Pediatric Migraine

Migraine Clinical Trial

Official title:
Cognitive Side Effects of Commonly Prescribed Medications in Pediatric Migraine

Clinical Trial Details — Status: Withdrawn

Administrative data
NCT number NCT00777218
Other study ID # 07-185
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date August 2007
Est. completion date July 2011

Study information
Verified date December 2020
Source University of South Alabama
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if there are significant differences in the side effects related to memory, repetition and recall among these three drugs when used in a pediatric population.

Recruitment information / eligibility
Status Withdrawn
Enrollment 0
Est. completion date July 2011
Est. primary completion date December 2010
Accepts healthy volunteers No
Gender All
Age group 8 Years to 17 Years
Eligibility Inclusion Criteria: - diagnosis of migraine with and without aura or chronic daily headache as defined by IHS - subjects must between the age of 8-17 (inclusive) Exclusion Criteria: - diagnosis of tension-type headache or cluster headache

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• propranolol
standard pediatric doses, based on body weight
• zonisamide
standard pediatric dosages, based on body weight
• topiramate
standard pediatric dosages, based on body weight

Locations
Country Name City State
United States University of South Alabama Department of Neurology Mobile Alabama

Sponsors (1)
Lead Sponsor Collaborator
University of South Alabama

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Record if memory, repetition or recall was impaired by subject during specific time frame on medication. 3 months
See also
  Status Clinical Trial Phase
Completed NCT05525611 - Cabergoline as a Preventive Treatment for Chronic Migraine N/A
Completed NCT06192173 - Patent Foramen Ovale Closure in Migraine
Recruiting NCT03832998 - Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine Phase 3
Enrolling by invitation NCT04196933 - Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma N/A
Not yet recruiting NCT06428838 - Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context Phase 3
Completed NCT06304675 - Manageable Environmental Factors in Migraine
Completed NCT04084314 - Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study Phase 4
Recruiting NCT05517200 - Pilot Study for a Machine Learning Test for Migraine
Completed NCT04179474 - Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine Phase 1
Recruiting NCT04603976 - Registry for Migraine - Clinical Core Phase 4
Completed NCT03597529 - CHOCOlate MeLatonin for AdolescenT MigrainE Phase 2
Completed NCT04197349 - Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman Phase 1
Recruiting NCT05891808 - miR-155 Expression in Episodic and Chronic Migraine
Active, not recruiting NCT05064371 - Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan Phase 3
Suspended NCT04069572 - Vibratory Stimulation for the Treatment of Chronic Pain N/A
Not yet recruiting NCT04859374 - Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach N/A
Not yet recruiting NCT03083860 - Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions. N/A
Completed NCT02905227 - A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder Phase 1
Enrolling by invitation NCT02532023 - The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients Phase 4
Completed NCT02108678 - One-Day Intervention for Depression and Impairment in Migraine Patients N/A